US FDA Wants To Know What Doctors Know About Abuse-Deterrent Opioids
Healthcare professionals will be asked about their knowledge of abuse-deterrent opioid formulations along with their views on prescription drug promotions.
You may also be interested in...
Upcoming research projects will look at presentation of FDA approval status, timing of disease awareness ads, and healthcare professional views.
Mandatory training could be reserved for physicians who want to prescribe opioids for longer-term use, as opposed to those who would prescribe recommended amounts in blister packs; evidence that blister packs would affect prescribing still is needed, however.
US FDA commissioner tells House committee that culture changes – and label changes – are among the actions the agency is pursuing to address the opioid crisis.